Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Deutetrabenazine Use in Chinese Huntington’s Disease Chorea
ChiCTR2300077341Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deutetrabenazine in Huntington disease (HD), sponsored by West China Hospital of Sichuan University. Primary endpoint: Unified Huntington's Disease Rating Scale (UHDRS) total maximal chorea (TMC) score. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
deutetrabenazine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on ChiCTR2300077341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077341.